Detection of preclinical parkinson disease in at-risk family members with use of [123I]-CIT and SPECT: An exploratory study

Demetrius M. Maraganore; Michael K. O'Connor; James H. Bower; Karen M. Kuntz; Shannon K. Mcüonnell; Daniel J. Schah; Walter A. Rocca

doi:10.4065/74.7.681

Detection of preclinical parkinson disease in at-risk family members with use of [123I]-CIT and SPECT: An exploratory study

Demetrius M. Maraganore, Michael K. O'Connor, James H. Bower, Karen M. Kuntz, Shannon K. Mcüonnell, Daniel J. Schah, Walter A. Rocca

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Objective: To explore whether the radioligand 2carboxymethoxy-3-(4-[123I] iodophenyl) tropane ([123I]CIT) and single-photon emission computed tomography (SPECT) can detect decreased striatal uptake in at-risk relatives of patients with Parkinson disease (PD). Patients and Methods: Ten PD patients, 10 at-risk first-degree relatives of PD patients, and 10 controls underwent [123I]-CIT and SPECT brain imaging. Their striatal uptake ratios were compared. Results: Age-adjusted specific to nonspecific striatal uptake ratios were lower in patients compared with controls and with relatives; however, ratios were similar in relatives and controls. Among relatives, ratios were consis-tently lower in subgroups postulated to be at higher risk for preclinical PD. Conclusion: Our findings provide preliminary support that [¹²³I]β-CIT and SPECT may detect decreased striatal uptake in relatives of PD patients postulated to be at higher risk for PD.

Original language	English (US)
Pages (from-to)	681-685
Number of pages	5
Journal	Mayo Clinic Proceedings
Volume	74
Issue number	7
DOIs	https://doi.org/10.4065/74.7.681
State	Published - 1999
Externally published	Yes

Bibliographical note

Funding Information:
This study was supported in part by Guilford Pharmaceuticals, by grant NS33978 from the National Institute of Neurological Disorders and Stroke, and by Mayo Foundation.

Publisher link

10.4065/74.7.681

Find It

Find It at U of M Libraries

Cite this

@article{724bfb2f6cd44fff986de8a8a9ec836b,

title = "Detection of preclinical parkinson disease in at-risk family members with use of [123I]-CIT and SPECT: An exploratory study",

abstract = "Objective: To explore whether the radioligand 2carboxymethoxy-3-(4-[123I] iodophenyl) tropane ([123I]CIT) and single-photon emission computed tomography (SPECT) can detect decreased striatal uptake in at-risk relatives of patients with Parkinson disease (PD). Patients and Methods: Ten PD patients, 10 at-risk first-degree relatives of PD patients, and 10 controls underwent [123I]-CIT and SPECT brain imaging. Their striatal uptake ratios were compared. Results: Age-adjusted specific to nonspecific striatal uptake ratios were lower in patients compared with controls and with relatives; however, ratios were similar in relatives and controls. Among relatives, ratios were consis-tently lower in subgroups postulated to be at higher risk for preclinical PD. Conclusion: Our findings provide preliminary support that [123I]β-CIT and SPECT may detect decreased striatal uptake in relatives of PD patients postulated to be at higher risk for PD.",

author = "Maraganore, {Demetrius M.} and O'Connor, {Michael K.} and Bower, {James H.} and Kuntz, {Karen M.} and Mc{\"u}onnell, {Shannon K.} and Schah, {Daniel J.} and Rocca, {Walter A.}",

note = "Funding Information: This study was supported in part by Guilford Pharmaceuticals, by grant NS33978 from the National Institute of Neurological Disorders and Stroke, and by Mayo Foundation. ",

year = "1999",

doi = "10.4065/74.7.681",

language = "English (US)",

volume = "74",

pages = "681--685",

journal = "Mayo Clinic Proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "7",

}

TY - JOUR

T1 - Detection of preclinical parkinson disease in at-risk family members with use of [123I]-CIT and SPECT

T2 - An exploratory study

AU - Maraganore, Demetrius M.

AU - O'Connor, Michael K.

AU - Bower, James H.

AU - Kuntz, Karen M.

AU - Mcüonnell, Shannon K.

AU - Schah, Daniel J.

AU - Rocca, Walter A.

N1 - Funding Information: This study was supported in part by Guilford Pharmaceuticals, by grant NS33978 from the National Institute of Neurological Disorders and Stroke, and by Mayo Foundation.

PY - 1999

Y1 - 1999

N2 - Objective: To explore whether the radioligand 2carboxymethoxy-3-(4-[123I] iodophenyl) tropane ([123I]CIT) and single-photon emission computed tomography (SPECT) can detect decreased striatal uptake in at-risk relatives of patients with Parkinson disease (PD). Patients and Methods: Ten PD patients, 10 at-risk first-degree relatives of PD patients, and 10 controls underwent [123I]-CIT and SPECT brain imaging. Their striatal uptake ratios were compared. Results: Age-adjusted specific to nonspecific striatal uptake ratios were lower in patients compared with controls and with relatives; however, ratios were similar in relatives and controls. Among relatives, ratios were consis-tently lower in subgroups postulated to be at higher risk for preclinical PD. Conclusion: Our findings provide preliminary support that [123I]β-CIT and SPECT may detect decreased striatal uptake in relatives of PD patients postulated to be at higher risk for PD.

AB - Objective: To explore whether the radioligand 2carboxymethoxy-3-(4-[123I] iodophenyl) tropane ([123I]CIT) and single-photon emission computed tomography (SPECT) can detect decreased striatal uptake in at-risk relatives of patients with Parkinson disease (PD). Patients and Methods: Ten PD patients, 10 at-risk first-degree relatives of PD patients, and 10 controls underwent [123I]-CIT and SPECT brain imaging. Their striatal uptake ratios were compared. Results: Age-adjusted specific to nonspecific striatal uptake ratios were lower in patients compared with controls and with relatives; however, ratios were similar in relatives and controls. Among relatives, ratios were consis-tently lower in subgroups postulated to be at higher risk for preclinical PD. Conclusion: Our findings provide preliminary support that [123I]β-CIT and SPECT may detect decreased striatal uptake in relatives of PD patients postulated to be at higher risk for PD.

UR - http://www.scopus.com/inward/record.url?scp=0032989409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032989409&partnerID=8YFLogxK

U2 - 10.4065/74.7.681

DO - 10.4065/74.7.681

M3 - Article

C2 - 10405696

AN - SCOPUS:0032989409

SN - 0025-6196

VL - 74

SP - 681

EP - 685

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

IS - 7

ER -

Detection of preclinical parkinson disease in at-risk family members with use of [123I]-CIT and SPECT: An exploratory study

Abstract

Bibliographical note

Publisher link

Find It

Other files and links

Fingerprint

Cite this